3 days Ago By ABMN Staff
Stock analysts at StockNews.com initiated coverage on shares of Alimera Sciences ( NASDAQ:ALIM – Get Free Report ) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the company. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. HC Wainwright lowered Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.
00 price target on the stock. in a research note on Tuesday, June 25th. Finally, Alliance Global Partners reaffirmed a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.
Check Out Our Latest Stock Report on ALIM Alimera Sciences Stock Down 0.2 % Alimera Sciences ( NASDAQ:ALIM – Get Free Report ) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.
06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02).
Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%.
The firm had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.76 million.
As a group, sell-side analysts anticipate that Alimera Sciences will post -0.13 earnings per share for the current fiscal year. Institutional Trading of Alimera Sciences Several hedge funds have recently bought and sold shares of ALIM.
Deltec Asset Management LLC bought a new position in shares of Alimera Sciences in the second quarter valued at $690,000. Vanguard Group Inc. increased its holdings in Alimera Sciences by 61.
1% during the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares in the last quarter.
Ancora Advisors LLC purchased a new stake in shares of Alimera Sciences in the first quarter worth approximately $915,000. Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences in the first quarter worth approximately $83,000. Finally, Hillsdale Investment Management Inc.
bought a new position in shares of Alimera Sciences in the first quarter valued at approximately $169,000. Institutional investors and hedge funds own 99.83% of the company’s stock.
About Alimera Sciences ( Get Free Report ) Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Read More Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter ..
